| 前收盘价格 | 108.88 |
| 收盘价格 | 109.93 |
| 成交量 | 467,631 |
| 平均成交量 (3个月) | 1,135,591 |
| 市值 | 6,440,157,184 |
| 预期市盈率 (P/E Forward) | 2.00 |
| 价格/销量 (P/S) | 14.03 |
| 股市价格/股市净资产 (P/B) | 8.67 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2025 |
| 营业毛利率 | -30.57% |
| 营业利益率 (TTM) | -19.39% |
| 稀释每股收益 (EPS TTM) | -2.27 |
| 季度收入增长率 (YOY) | 24.60% |
| 总债务/股东权益 (D/E MRQ) | 14.09% |
| 流动比率 (MRQ) | 6.49 |
| 营业现金流 (OCF TTM) | -45.97 M |
| 杠杆自由现金流 (LFCF TTM) | -17.66 M |
| 资产报酬率 (ROA TTM) | -6.68% |
| 股东权益报酬率 (ROE TTM) | -20.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Glaukos Corporation | 看涨 | 看跌 |
AIStockmoo 评分
3.1
| 分析师共识 | 1.5 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | 4.0 |
| 平均 | 3.13 |
|
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 3.33% |
| 机构持股比例 | 101.71% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Brown Capital Management Llc | 30 Sep 2025 | 762,760 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 145.00 (UBS, 29.31%) | 购买 |
| 145.00 (Truist Securities, 29.31%) | 购买 | |
| 中 | 123.50 (10.14%) | |
| 低 | 103.00 (Goldman Sachs, -8.14%) | 购买 |
| 平均值 | 125.13 (11.59%) | |
| 总计 | 8 购买 | |
| 平均价格@调整类型 | 99.01 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| UBS | 23 Dec 2025 | 145.00 (29.31%) | 购买 | 116.18 |
| Truist Securities | 18 Dec 2025 | 145.00 (29.31%) | 购买 | 113.21 |
| Citigroup | 11 Dec 2025 | 125.00 (11.48%) | 购买 | 109.23 |
| 30 Oct 2025 | 113.00 (0.78%) | 购买 | 87.80 | |
| Needham | 09 Dec 2025 | 125.00 (11.48%) | 购买 | 106.87 |
| 30 Oct 2025 | 117.00 (4.34%) | 购买 | 87.80 | |
| BTIG | 30 Oct 2025 | 116.00 (3.45%) | 购买 | 87.80 |
| 20 Oct 2025 | 104.00 (-7.25%) | 购买 | 79.47 | |
| JP Morgan | 30 Oct 2025 | 120.00 (7.02%) | 购买 | 87.80 |
| Wells Fargo | 30 Oct 2025 | 122.00 (8.80%) | 购买 | 87.80 |
| 27 Oct 2025 | 120.00 (7.02%) | 购买 | 75.68 | |
| Goldman Sachs | 01 Oct 2025 | 103.00 (-8.14%) | 购买 | 83.19 |
| 显示更多 | ||||
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 16 Dec 2025 | 公告 | Glaukos Announces Participation in J.P. Morgan Healthcare Conference |
| 03 Nov 2025 | 公告 | Glaukos Announces Participation in Upcoming Investor Conferences |
| 29 Oct 2025 | 公告 | Glaukos Announces Third Quarter 2025 Financial Results |
| 20 Oct 2025 | 公告 | Glaukos Announces FDA Approval of Epioxa™ |
| 14 Oct 2025 | 公告 | Glaukos Innovation to be Highlighted at the 2025 American Academy of Ophthalmology Annual Meeting |
| 08 Oct 2025 | 公告 | Glaukos to Release Third Quarter 2025 Financial Results after Market Close on October 29 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合